Drug Profile
Myoinositol trispyrophosphate - NormOxys
Alternative Names: OXY 111ALatest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator NormOxys
- Developer NormOxys; University of Zurich
- Class Cyclohexanes; Small molecules; Sugar alcohols
- Mechanism of Action Haemoglobin modulators; Protein-serine-threonine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Chronic heart failure; Obesity
Most Recent Events
- 08 Sep 2021 No development reported - Phase-I/II for Cancer in Switzerland (IV)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA (IV, Infusion)
- 28 Aug 2015 No development reported - Preclinical for Obesity in USA (IV)